公开(公告)号：US20230241112A1

公开(公告)日：2023-08-03

申请号：US18170690

申请日：2023-02-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/2818 ,  C07K7/06 ,  C07K14/5434 ,  A61P35/02 ,  A61K39/001102 ,  A61K45/06 ,  C12N5/0636 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/12 ,  C07K16/244 ,  A61K39/39558 ,  C07K16/2821 ,  A61K38/08 ,  C07K14/4748 ,  A61K2039/5156 ,  A61K45/05

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230241109A1

公开(公告)日：2023-08-03

申请号：US18164413

申请日：2023-02-03

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/2818 ,  C07K7/06 ,  C07K14/5434 ,  A61P35/02 ,  A61K39/001102 ,  A61K45/06 ,  C12N5/0636 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/12 ,  C07K16/244 ,  A61K39/39558 ,  C07K16/2821 ,  A61K38/08 ,  C07K14/4748 ,  A61K2039/5156 ,  A61K45/05

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220226376A1

公开(公告)日：2022-07-21

申请号：US17576866

申请日：2022-01-14

Applicant: Immatics Biotechnologies GmbH

Inventor： Ricarda HANNEN ,  Jens HUKELMANN ,  Florian KOEHLER ,  Daniel Johannes KOWALEWSKI ,  Heiko SCHUSTER ,  Oliver SCHOOR ,  Michael ROEMER ,  Chih-Chiang TSOU ,  Jens FRITSCHE

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/00 ,  C12N5/0783 ,  C07K14/47

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20210137985A1

公开(公告)日：2021-05-13

申请号：US17150110

申请日：2021-01-15

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20210060078A1

公开(公告)日：2021-03-04

申请号：US17097798

申请日：2020-11-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20210060074A1

公开(公告)日：2021-03-04

申请号：US17089499

申请日：2020-11-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200323916A1

公开(公告)日：2020-10-15

申请号：US16914135

申请日：2020-06-26

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200323911A1

公开(公告)日：2020-10-15

申请号：US16900417

申请日：2020-06-12

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200323909A1

公开(公告)日：2020-10-15

申请号：US16900360

申请日：2020-06-12

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200268798A1

公开(公告)日：2020-08-27

申请号：US16864929

申请日：2020-05-01

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.